Novanta

Novanta, Inc. engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products. The Vision segment offers a range of medical grade technologies, including medical insufflators, pumps and related disposables, surgical displays and operating room integration technologies, optical data collection and machine vision technologies, radio frequency identification technologies, thermal printers, spectrometry technologies, and embedded touch screen solutions. The Precision Motion segment includes optical encoders, precision motor and motion control technology, air bearing spindles, and precision machined components to customers. The company was founded in 1968 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novanta achieves record-breaking 2022 results, eyes growth opportunities

Novanta's strong financial performance in 2022, driven by record sales and profitability, positions the company for continued success.
While facing challenges such as margin pressures and operational disruptions, Novanta's strategic strengths in medical markets and growth opportunities in new product development pave the way for future growth.
With a focus on efficiency, innovation, and market diversification, Novanta is poised to capitalize on growth prospects in 2023 and beyond.
Overall, Novanta's robust performance, strategic initiatives, and financial stability underscore its resilience and potential for sustained growth in the coming years.

Novanta excels in Q1 with strong medical market growth

Novanta's Q1 performance showcased robust revenue growth, particularly in medical markets and North America. The company's strategic focus on new products and margin expansion positions it well for future success despite challenges in certain regions and segments.

Novanta excels in Q2 2023, eyes growth amid market challenges

Novanta's Q2 performance was robust, driven by strong sales in medical markets and strategic growth initiatives.
Challenges include declines in microelectronics and China market, but opportunities lie in new product launches and recovery expectations.
The company's focus on innovation, backlog reduction, and margin expansion positions it well for future growth.
Overall, Novanta exceeded expectations for margins and profits, with a positive outlook for 2024.

Novanta reports solid Q3 performance, eyes new product supercycle

Novanta delivered a strong Q3 performance, exceeding expectations in margins, profit, and cash flow.
The company remains confident in its long-term outlook, focusing on innovation and upcoming product launches.
Despite short-term challenges, Novanta is committed to executing its growth strategy and expanding gross margins.

Novanta reports record revenue in 2023, eyes growth in medical markets

Novanta delivered a solid performance in 2023, achieving record revenue, gross margin expansion, and profit despite market challenges.
The company's focus on new product launches, intelligent subsystems, and growth in medical solutions segment positions it for continued success in 2024.
Challenges from the macroeconomic environment and product ramp downs need to be addressed to ensure sustained growth and profitability.
Opportunities from acquisitions, new product launches, and revenue streams in medical markets offer avenues for future growth and cash flow.

Novanta reports solid Q2 performance, eyes growth through new products

Novanta's Q2 2024 earnings call showcased strong financial performance and strategic priorities for growth.
While facing challenges in certain markets, the company's focus on new products and margin expansion bodes well for the future.
Analysts are keen on revenue drivers, margin expansion, and segment performance as key areas of interest.

Novanta reports solid Q3 earnings, eyes growth amidst short-term challenges

Novanta's Q3 2024 performance reflects steady revenue growth and improved profitability, supported by strong bookings and new product revenue confirmations.
While facing short-term challenges in Q4 2024, the company remains optimistic about robust business growth in 2025, emphasizing new product launches and margin expansion.
Guidance for Q4 2024 and full year 2024 indicates a strategic focus on organic growth, margin improvement, and acquisitions to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novanta (NOVT) delivered earnings and revenue surprises of 6.35% and 4.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Novanta (NOVT) Surpasses Q4 Earnings and Revenue Estimates

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2021. Financial Highlights Three Months Ended December 31,     Year Ended December 31,   (In millions, except per share amounts) 2021     2020     2021     2020   GAAP                               Revenue $ 199.0     $ 147.5     $ 706.8     $ 590.6

Novanta Announces Financial Results for the Fourth Quarter and Full Year 2021

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Partners with MassRobotics to Advance Next Generation of Robotics

Novanta Partners with MassRobotics to Advance Next Generation of Robotics

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter and full year 2021 results on Tuesday, March 01, 2022. The Company will host a conference call on Tuesday, March 01, 2022, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be ac

Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, March 01, 2022

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and Charlie Webster, Executive Vice President, are scheduled to present at the CJS Securities 22nd Annual New Ideas for the New Year Investor Conference, which is being held virtually, on Wednesday, January 12, 2022. About Novanta Novanta is a leading global supplier of

Novanta to Present at the CJS Securities 22nd Annual New Ideas for the New Year Investor Conference on Wednesday, January 12, 2022

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chairperson and Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the J.P. Morgan Healthcare Conference, which is being held in person, on Tuesday, January 11, 2022, in San Francisco, California. About Novanta Novanta is a leading global supplier

Novanta to Present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022

Novanta, Inc. (NOVT) CEO Matthijs Glastra on Q3 2021 Results - Earnings Call Transcript

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq:NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2021. Financial Highlights Three Months Ended   (In millions, except per share amounts) October 1,     October 2,     2021     2020   GAAP               Revenue $ 177.7     $ 142.9   Operating Income $ 15.3     $ 11.9   Consolidated Net Income $ 13.6     $ 8.3   Diluted EPS $ 0

Novanta Announces Financial Results for the Third Quarter 2021

Novanta (NOVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novanta (NOVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chairperson and Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird's 2021 Global Industrial Conference on Wednesday, November 10, 2021, which is being held virtually. About Novanta Novanta is a leading global supplier of core technology

Novanta to Present at Baird's 2021 Global Industrial Conference on Wednesday, November 10, 2021

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2021 results on Tuesday, November 09, 2021. The Company will host a conference call on Tuesday, November 09, 2021, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed on

Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, November 09, 2021

Novanta (NOVT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Novanta (NOVT) Moves 4.2% Higher: Will This Strength Last?

Novanta (NOVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Novanta (NOVT) Rating Upgrade to Strong Buy

ScanSource

Watts Water Technologies

PVH, WTS, SCSC, and NOVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2021

Top Ranked Momentum Stocks to Buy for September 3rd

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chairperson and Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird's 2021 Global Healthcare Conference on Wednesday, September 15, 2021, which is being held virtually. About Novanta Novanta is a leading global supplier of core technolog

Novanta to Present at Baird's 2021 Global Healthcare Conference on Wednesday, September 15, 2021

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has completed the acquisitions of Schneider Electric Motion USA Inc. (“SEM”) and ATI Industrial Automation Inc. (“ATI”). "SEM and ATI are fantastic businesses which are excellent strategic additions to Novanta, expanding our positions in high growth markets,” said Matthijs Glastra, Chairperson and CEO of No

Novanta Completes Acquisitions of SEM and ATI and Updates Financial Guidance

Novanta, Inc. (NOVT) CEO Matthijs Glastra on Q2 2021 Results - Earnings Call Transcript

Novanta Inc (NASDAQ: NOVT) reported second-quarter FY21 revenue growth of 15.8% year-on-year to $167.5 million, beating the analyst consensus of $164.3 million. The revenue reported an 11.4% organic growth.

Novanta Q2 Result Tops Estimates, Raises FY21 Outlook

Novanta (NOVT) delivered earnings and revenue surprises of 21.57% and 2.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Novanta (NOVT) Q2 Earnings and Revenues Surpass Estimates

Shares of Novanta (NASDAQ:NOVT) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 29.17% over the past year to $0.62, which beat the estimate of $0.51.

Novanta: Q2 Earnings Insights

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2021. Financial Highlights Three Months Ended   (In millions, except per share amounts) July 2,   July 3,     2021   2020   GAAP             Revenue $ 167.5   $ 144.7   Operating Income $ 16.0   $ 13.7   Consolidated Net Income $ 11.7   $ 11.7   Diluted EPS $ 0.33   $ 0.33

Novanta Announces Financial Results for the Second Quarter 2021

RICHMOND, Va.--(BUSINESS WIRE)--Harris Williams, a global investment bank specializing in M&A advisory services, announces it is advising ATI Industrial Automation (ATI) on its pending sale to Novanta Inc. (Nasdaq: NOVT; Novanta). Headquartered in Apex, North Carolina, ATI is a leading global developer and manufacturer of robot end-effector products. The transaction is being led by John Arendale, Jeff Perkins, Brandt Carr, Jenson Dunn and Caroline Inglesby of the Harris Williams Industrials

Harris Williams Advises ATI Industrial Automation on its Pending Sale to Novanta Inc.

Novanta Inc (NASDAQ: NOVT) inked an agreement to acquire ATI Industrial Automation for $172 million upfront in cash and earnout consideration based on 2021 financial performance.  Additionally, Novanta will also grant performance stock units.

Novanta To Acquire ATI For $172M Cash Plus Earnout

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has reached an agreement to acquire privately held ATI Industrial Automation ("ATI") for $172 million upfront in cash and additional contingent cash payments associated with 2021 financial performance. In addition, to further incentivize future financial performance, the Company will also grant performance

Novanta Announces Agreement to Acquire ATI

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2021 results on Tuesday, August 10, 2021. The Company will host a conference call on Tuesday, August 10, 2021, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed onlin

News for Novanta Stock (NOVT)